Ronald Gelbman has a rich history in the pharmaceutical sector, particularly through his long-standing relationship with Haemonetics Corporation. Although specific numbers about his holdings are not disclosed, his wealth was significantly tied to the company. He served as the Interim...

Ronald Gelbman has a rich history in the pharmaceutical sector, particularly through his long-standing relationship with Haemonetics Corporation. Although specific numbers about his holdings are not disclosed, his wealth was significantly tied to the company. He served as the Interim CEO, a position he held temporarily which usually does not come with stock grants or options. His decision to step into this role came during a critical transition for the company, and while in charge, he received a monthly salary of $67,500. Notably, his past position at Johnson & Johnson likely influenced stock values in his portfolio, detailing a career where he understood the nuances of market fluctuations and held a considerable stake in the firms he led.